医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Imricor Announces First Sales Collaboration With Philips

2020年08月04日 PM09:00
このエントリーをはてなブックマークに追加


 

MINNEAPOLIS

Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the worldwide leader in MRI-guided cardiac ablation products, is pleased to announce the first sales collaboration with Philips, a global leader in healthcare technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200804005317/en/

Imricor announces first sales partnership with Philips. (Photo: Business Wire)

Imricor announces first sales partnership with Philips. (Photo: Business Wire)

The sales collaboration provides Philips non-exclusive rights to re-sell Imricor’s Advantage-MR System, along with Philips’ industry-leading MRI scanners in European countries that recognize the CE mark. This agreement is the first such agreement signed by Imricor.

Imricor’s Chair and CEO, Steve Wedan said: “This agreement is a major milestone for Imricor, allowing Philips to take the lead on driving iCMR lab adoption and enabling us to focus on supporting utilization, growing our portfolio of consumable devices and expanding our indications for use. In this way, we each leverage our strengths as we work together to deliver a new standard of care in the treatment of cardiac arrhythmias.”

The Imricor products are specifically designed to enable cardiac ablations under real-time MRI guidance. Imricor is the first and only company to offer a fully MR conditional EP recorder/stimulator system and cardiac ablation catheters for use in the MRI environment.

“Treatment procedures guided by MR represent an emerging field that extends the value of MR and complements established X-ray-based image-guided therapy systems,” said Arjen Radder, General Manager MR Business at Philips. “By working with Imricor we can support healthcare providers to offer MRI-guided cardiac ablation procedures for their patients.”

This collaboration is the latest achievement in the partnership between Imricor and Philips, which began in 2010.

“We are very proud to have a sales partnership with a company like Philips. We look forward to working with the talented Philips sales teams to leverage the extensive and outstanding relationships they have with customers, to help build new iCMR suites, and to identify potential customers that already have access to 1.5T compatible MRI systems.” Greg Englehardt, Director of Sales at Imricor.

About Imricor

Please visit http://imricor.com/investors/about-imricor/ for more information about Imricor, Foreign Ownership Restrictions, and Forward-Looking Statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005317/en/

CONTACT

Investors:

Steve Wedan

Executive Chair, President and CEO

Email: steve.wedan@imricor.com

Carrie Barrack

Senior Advisor, Cato & Clive

Email: carrie@catoandclive.com

Phone: +61 422 464 028

Rest of World Media:

Nick Twohy

Director of Marketing, Imricor

Email: nick.twohy@imricor.com

Phone: +1 952 818 8407

Australia Media:

Carrie Barrack

Senior Advisor, Cato & Clive

Email: carrie@catoandclive.com

Mobile: +61 422 464 028

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • MEDIROM Healthcare Technologies Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering on NASDAQ
  • COVAXX Announces $2.8 Billion in Advance Purchase Commitments to Deliver More Than 140 Million Vaccine Doses to Emerging Countries
  • Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
  • Celltrion completes enrolment for global Phase II clinical trial with COVID-19 treatment candidate CT-P59
  • 医療従事者が登壇 ウィズコロナ時代の最先端医療セミナー開催 ~遠隔重症患者診療・スマートホスピタル構想について語る!~